| Autor: |
Fiander, A.N., Nimako, M., Adams, M., Evans, A.S., Mann, S., West-moreland, D., Stacey, S., Hickling, J., Inglis, S., Borysiewicz, L.K. |
| Zdroj: |
European Journal of Cancer; November 1995, Vol. 31 Issue: 6 pS123-S123, 1p |
| Abstrakt: |
A phase 1 study aiming to generate MHC class 1 restricted HPV specific cytotoxic lymphocytes (CTL's) in cervical cancer patients using vaccinia recombinant (TA-HPV) immunotherapy encoding E6 and E7 open reading frames of HPV 16 and 18. In addition the trial monitors toxicity and environmental contamination.The construct has been used to vac-cinate 8 patients to date with established cervical carcinoma by conventional scarification under strict isolation to avoid environmental release. Assays have been developed to detect HPV E6 and E7 specific CTL using adenovirus recombinants for secondary in vitrostimulation to avoid non-specific cytotoxicityClinical follow-up is still in progress but no side-effects of vaccination have been observed up to a year post vaccination, despite subsequent radio- and chemotherapy. No environmental contamination has been detected and the recombinant has been shown to be stable after human inoculation. Serological response to the inserted sequences has been observed in some of the patients and cytotoxicity assays suggest the development of HPV specific CTL.Adjuvant immunotherapy for women with cervical carcinomas using a vaccinia recombinant agent encoding HPV 16/18 E6 & E7 appears promising. Further work is planned to define dosage scheduling and the ideal recipient group. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect